Organogenesis Holdings Inc. (US68621F1021)
XSTU 
Summary
US68621F1021 Chart
Organogenesis Holdings: ReNu And New LCD Offer A Rebound Scenario
ORGO's main drivers are its advanced wound-care and surgical biologics that leverage its evidence-rich portfolio. They have a Phase 3 trial on ReNu knee-osteoarthritis with data anticipated by September 2025. Its potential BLA filing could eventually unlock the injectable OA market. CMS skin-substitute LCD was postponed to January 2026. This regulatory standard will require more robust evidence for insurance reimbursements.
Organogenesis Holdings Inc. (ORGO) Q1 2025 Earnings Call Transcript
Organogenesis Holdings Inc. (NASDAQ:ORGO ) Q1 2025 Earnings Conference Call May 8, 2025 5:00 PM ET Company Participants Gary Gillheeney - President and Chief Executive Officer David Francisco - Chief Financial Officer Conference Call Participants Aaron Wukmir - Lake Street Capital Markets Ryan Zimmerman - BTIG Ross Osborn - Cantor Fitzgerald Operator Welcome, ladies and gentlemen, to the First Quarter 2025 Earnings Conference Call for Organogenesis Holdings Inc. [Operator Instructions] Please note that this conference call is being recorded and that the recording will be available on the company's website for replay shortly. Before we begin, I would like to remind everyone that our remarks today may contain forward-looking statements that are based on the current expectations of management and involve inherent risks and uncertainties that could cause actual results to differ materially from those indicated, including the risks and uncertainties described in the company's filings with the Securities and Exchange Commission, including Item 1A, Risk Factors, of the company's most recent annual report and its subsequently filed quarterly reports.
Organogenesis (ORGO) Reports Q1 Loss, Lags Revenue Estimates
Organogenesis (ORGO) came out with a quarterly loss of $0.13 per share versus the Zacks Consensus Estimate of $0.04. This compares to loss of $0.02 per share a year ago.
Organogenesis Holdings Inc. Dividends
Organogenesis Holdings Inc. Earnings
| 9 May 2025 Date | | - Cons. EPS | - EPS |
| 26 Feb 2025 Date | | 0.02 Cons. EPS | 0.07 EPS |
| 12 Nov 2024 Date | | - Cons. EPS | 0.1 EPS |
| 7 Nov 2024 Date | | - Cons. EPS | - EPS |
| 8 Aug 2024 Date | | - Cons. EPS | - EPS |
| 9 May 2025 Date | | - Cons. EPS | - EPS |
| 26 Feb 2025 Date | | 0.02 Cons. EPS | 0.07 EPS |
| 12 Nov 2024 Date | | - Cons. EPS | 0.1 EPS |
| 7 Nov 2024 Date | | - Cons. EPS | - EPS |
| 8 Aug 2024 Date | | - Cons. EPS | - EPS |
Organogenesis Holdings Inc. (US68621F1021) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Organogenesis Holdings Inc. ever had a stock split?
Organogenesis Holdings Inc. Profile
| Drug Manufacturers - Specialty & Generic Industry | Healthcare Sector | Mr. Gary S. Gillheeney Sr. CEO | XSTU Exchange | US68621F1021 ISIN |
| US Country | 869 Employees | - Last Dividend | - Last Split | 5 Jan 2017 IPO Date |
Overview
Organogenesis Holdings Inc. is a pioneering regenerative medicine company dedicated to developing, manufacturing, and commercializing innovative solutions primarily for the advanced wound care, and surgical and sports medicine markets within the United States. With its foundation dating back to 1985, Organogenesis Holdings Inc. has established its headquarters in Canton, Massachusetts. The company is renowned for its commitment to enhancing patient care by providing cutting-edge regenerative medicine products and therapies. Through its direct sales representatives and independent agencies, Organogenesis serves a diverse clientele, including hospitals, wound care centers, government facilities, ambulatory service centers, and physician offices.
Products and Services
Affinity: An amniotic membrane product preserving viable cells, growth factors/cytokines, and extracellular matrix (ECM) proteins from the native tissue, offering advanced wound care solutions.
Novachor: Similar to Affinity, Novachor is a chorion membrane product that retains viable cells, growth factors/cytokines, and ECM proteins, aimed at enhancing wound healing processes.
Apligraf: A pioneering bioengineered living cell therapy that produces a broad spectrum of cytokines and growth factors, designed for the treatment of wounds.
Dermagraft: A bioengineered product known for producing human collagen, ECM proteins, cytokines, and growth factors, contributing to effective wound repair.
NuShield: A dehydrated placental tissue product covering both amnion and chorion membranes to keep the spongy/intermediate layer intact, designed for wound care management.
PuraPly AM: This antimicrobial barrier is known for its conformability and fluid drainage capabilities, offering a solution in the management of wound infections.
FortiShield: A biosynthetic wound matrix developed for use as a temporary protective covering for wounds, part of the advanced wound care line-up.
PuraPly MZ: A micronized particulate version of PuraPly, designed specifically for the management of open wounds in a surgical setting.
CYGNUS Dual: A dehydrated placental tissue product, preserved meticulously to retain the ECM scaffold, offering support in wound care.
ReNu: A pipeline product, ReNu is a cryopreserved suspension aimed to support the healing of soft tissues, showcasing the company's ongoing innovation.
PuraForce: Another bioengineered product in the pipeline, PuraForce is a porcine collagen surgical matrix intended for soft tissue reinforcement applications.
TransCyte: A bioengineered tissue designed for the treatment of partial thickness burns, reflecting the company's commitment to addressing a broad range of medical challenges.
Contact Information
